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A B S T R A C T
Malaria is a parasitic and vector determined blood-conceived infectious disease transmitted
through infected mosquitoes. Anti-malarial drug resistance is a major health problem, which
hinders the control of malaria. A Results of a survey of drug-resistant malaria demonstrated
safe proclivity to nearby all anti-malarial regimes accessible except from artemisinin and its
derivatives. Artemether is a BCS class IV drug effective against acute and severe falciparum
malaria; hence there is a strong need to improve its solubility. Silica is one of the most widely
studied excipients. Silica can be used in solubility enhancement by preparing its solid solution/
dispersion with the drug. The objective of this research was to improve dissolution rate of
Artemether using non-precipitated porous silica (Aeroperl 300 Pharma) and precipitated silica
like EXP. 9555, EXP. 9560, and EXP. 9565. Specific surface area calculated from BET method of
porous silicas viz. APL 300 (A), Exp. 9555 (B), Exp. 9560 (C), Exp. 9565 (D) was found to be
294.13 m2/g (A), 256.02 m2/g (B), 213.62 m2/g (C) and 207.22 m2/g (D) respectively.The drug release
from the developed formulation was found to be significantly higher as compared to neat
ARM. This improved solubility and release kinetics of ARM may be attributed to high surface
area, improved wettability and decreased crystallinity. Solid-state characterization of the de-
veloped optimized formulation F3 was carried out with respect to FTIR chemical imaging, XRD,
SEM, and DSC. All the porous silicas which we have explored in the present context showed
a significant capability as a carrier for solubility enhancement of ARM.
© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
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Drugs with poor aqueous solubility have low or erratic ab-
sorption and, subsequently poor bioavailability [1]. Some of the
drugs that belong to class IV of the biopharmaceutical clas-
sification system are characterized by poor permeability and
low aqueous solubility [2,3]. Current statistics report that
because of the low aqueous solubility, up to 40% of new chemi-
cal entities fail to reach the market despite revealing potential
pharmacodynamic activities.
Many potential compounds often drop out on the way of
pharmaceutical development because of their insufficient oral
bioavailability. Consequently, a lot of efforts have been made
to increase dissolution rate of such drugs. Different ap-
proaches to enhance the dissolution rate of poorly soluble drugs
include solid dispersions prepared by spray-drying [4–6], freeze-
drying [7], mechanical milling [8,9], hot melt extrusion [10,11],
supercritical fluid precipitation [12,13], co-crystal formation [14],
inclusion complexes using cyclodextrins [15], liquid antisolvent
precipitation [16], loading onto porous carriers [17], amor-
phous solid dispersions by hot melt extrusion [18]. However,
most of these technologies face demerits of scale up issue and
economic challenge.
Malaria is a parasitic and vector determined blood-conceived
infectious disease transmitted through infected mosquitoes.
Anti-malarial drug resistance is a major health problem, which
hinders the control of malaria. Results of a survey of drug-
resistant malaria demonstrated safe proclivity to nearby all anti-
malarial regimes accessible except from artemisinin and its
derivatives. Artemisinin is an important type of antimalarial
drug, structurally characterized by incidence of a sesquiter-
pene lactone with a peroxide bridge [19,20]. Different types of
artemisinin derivatives have been synthesized viz. artemether,
artesunate, arteether, which are currently in use [21].
Artemether [ARM] (chemical structure as shown in Fig. 1)
is a potent antimalarial agent accessible for the treatment of
severe multiresistant malaria and is included in the WHO list of
essential medicines. It is active against Plasmodium vivax as well
as chloroquine-sensitive and chloroquine-resistant strains of
Plasmodium falciparum.ARM shows rapid onset of schizontocidal
action and is metabolized in the liver to a demethylated de-
rivative, dihydroartemisinin, which is indicated in the treatment
of cerebral malaria. However, the therapeutic potential of ARM
is significantly delayed due to its low oral bioavailability because
of its poor aqueous solubility [22,23].
Solvent evaporation method involves preparation of a so-
lution containing both carrier material and drug, and the
removal of the solvent resulting in the formation of the solid
powder mass. Preparation of SDs using solvent evaporation has
been successfully explored for the dissolution rate enhance-
ment of poorly water-soluble drugs [24–26]. In present study,
the potential of various porous silica to improve the dissolu-
tion of ARM has been studied. Silica is one of the most widely
studied excipients. It exists in amorphous to highly ordered
crystalline states. Silica is generally regarded as safe [27]. The
amorphous silica has many applications in pharmaceutics and
drug delivery such as glidant (flow promoter), carrier, thick-
ener and viscosity modifier, adsorbent and preservative.Various
reports are available in the literature implementing its use in
solubility enhancement by preparing its solid solution/
dispersion with the drug. For example solid dispersion
formulations using porous silicas [24,25] and bicalcutamide
using Aeroperl 300 (APL300) [28].
In this context, we have explored the use of porous silicas
like non-precipitated silica as APL 300 and precipitated porous
silicas viz. EXP. 9555, EXP. 9560, EXP. 9565 as a carrier and ad-
sorbent to formulate ARM:PS systems. All porous silicas had
an inert amorphous material consisting of colloidal silicon
dioxide with a significantly high pore volume and consistent
spherical shape. Silica exists in amorphous to highly ordered
crystalline states. It also has excellent flow and compressibil-
ity properties. Porous silicas in the ARM:PS system can
potentially resolve formulation issues associated with solid dis-
persions. In addition, porous silicas are less likely to promote
reversion of amorphous drug to crystalline state on storage of
solid dispersion due to its non-crystalline nature [28,29]. Solid
dispersion prepared using hydrophilic excipients often face soft-
ness and tackiness issues. To overcome such issues the use of
large amount of excipients is reported [30,31]. The use of such
excipients at higher amount often resulted into large tablet
weights, which is not acceptable practically. Hence, in this re-
search work we have explored different types of porous silicas
as a carrier system for dissolution rate enhancement of poorly
water-soluble drugs. ARM loading into porous silica by solvent
evaporation method was explored at various ratios. Molecu-
lar state of drug in the prepared samples was evaluated
using differential scanning calorimetry and powder X-ray
diffractometry. Surface morphology study was carried out using
scanning electron microscopy. The apparent solubility and dis-
solution behavior of ARM:PS systems were evaluated further.
2. Materials and methods
2.1. Materials
Artemether was obtained as a generous gift from IPCA Pvt. Ltd.
Mumbai, India. Aeroperl 300 pharma and other porous silicas
viz. EXP. 9555, EXP. 9560, EXP. 9565 were obtained from Evonik
Industries, Germany. Hard gelatin capsules IP were obtained
as a gift sample from ACG Associated Capsules Pvt. Ltd. India.
All other chemicals and solvents used were of analytical grade
and were procured from Merck India Ltd. All the materials were
used as received.Fig. 1 – Chemical structure of ARM.
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2.2. Methods
2.2.1. Preparation of ARM-PS systems
ARM:PS systems were prepared by solvent evaporation tech-
nique. ARM (1 gm) was dissolved in 5 mL of acetone under
stirring to form a transparent solution. After complete homog-
enization ratios as 1:1, 1:2 and 1:3 of respective porous silicas
were added in solvent system as shown in Table 1. The solu-
tion was covered with an aluminum foil and the solvent from
the clear solution was allowed to be evaporated by piercing 5–6
fine holes in the foil.The entire process was carried out at room
temperature with constant stirring. The process was contin-
ued until a solid fine product was obtained. The product was
dried in vacuum oven at 40 °C for 5 minute cycles until con-
stant weight was attained.The obtained product was pulverized
and passed through size 60# mesh sieve. The obtained product
was kept in a desiccator for further evaluation for various
parameters.
2.2.2. Saturation solubility study
The equilibrium solubility study of neat ARM and prepared
ARM:PS systems were carried out in 10 mL of distilled water
containing 1% SLS and phosphate buffer of pH 7.2 containing
1% SLS evaluated for maximum solubility of ARM and ARM:PS
system in respective dissolution media after 72 hr. By adding
an excess amount of neat ARM and ARM:PS system (F1–F12),
the samples were then sonicated for 15 min at room tempera-
ture. Thereafter, the test tubes (n = 3) were shaken for 72 hr at
37 ± 0.5 °C at a speed of 75 rpm on an orbital shaking
thermo stable incubator (Boekel Scientific, Germany). The
samples were centrifuged at 10,000 rpm for 15 min and fil-
tered through 0.45 μm millipore membrane filter.The first 1 mL
of the filtrate was discarded. The samples were then suitably
diluted with respective dissolution medium and analyzed at
211 nm on UV-spectrophotometer (UV-1601 PC, Shimadzu,
Japan).
2.2.3. In vitro release study
The in vitro drug dissolution properties of ARM:PS systems were
examined according to the USP basket method using disso-
lution apparatus (Electrolab Pvt. Ltd. India) at 37 ± 0.5 °C. Powder
samples equivalent to 40 mg of ARM:PS system (F1–F12) were
filled in hard gelatin capsules and were added to dissolution
media containing 1000 mL phosphate buffer of pH 7.2 with 1%
SLS (sodium lauryl sulfate) at a temperature of 37 ± 0.2 °C. The
solution was stirred with a rotating basket at 100 rpm. Aliquots
of 5.0 mL were withdrawn from each vessel at predeter-
mined time intervals (10, 20, 30, 40, 50, 60 and 120 min), filtered
over a cellulose acetate filter of 0.45 μ. At each time point, the
same volume of fresh preheated dissolution medium was re-
placed. The ARM concentration in each sampled aliquot was
determined using an ultraviolet visible spectrophotometer at
211 nm (UV-1601PC, Shimadzu, Japan).
2.2.4. Differential scanning calorimetry
DSC analysis was performed using Pyris-6 DSC Perkin Elmer
(USA). Approximately 4 mg of sample was placed in alumi-
num pan and crimped using a press. An empty aluminum pan
was used as a reference pan. Experiment was carried out in
nitrogen atmosphere 17 mL/min of nitrogen flow at a heating
rate of 10 °C/minute from 30 °C to 300 °C to obtain the endo-
thermic peaks.
2.2.5. X-ray diffraction analysis
The X-ray diffraction studies of pure ARM, APL 300, Exp. 9555,
Exp. 9560 and Exp. 9565 and all ARM:PS systems (F1–F12) with
porous silicas were recorded using ADVANCE D8 system with
CuKα radiation (Bruker, USA). XRD studies were carried out to
determine whether the sample is in crystalline, paracrystalline
or amorphous state. The voltage of 40 kV with current 20 mA
was set. The recording spectral range was set at 10° to 50° two
theta values using the Cu-target X-ray tube and Xe-filled de-
tector. The samples were placed in a zero background sample
holder and incorporated on a spinner stage.
2.2.6. Scanning electron microscopy
The particulate morphologies of ARM powder and ARM:PS
system (F3, F6, F9 and F12) were examined using XL 30 Model
JEOL 6800 scanning electron microscope (Japan). During
analysis double-sided carbon tape was affixed on aluminum
stubs over which powder samples of ARM and ARM-PS were
sprinkled. The radiation of platinum plasma beam using JFC-
1600 auto fine coater was targeted on aluminum stubs for its
coating to make a layer of 2 nm thickness above the sprinkled
powder for 30 min. Then, the samples were observed for mor-
phological characterization using a gaseous secondary electron
detector (working pressure: 0.8 Torr, acceleration voltage:
10–30.00 kV).
2.2.7. Powder flow properties
The parameters governing flow properties of ARM-PS systems
were calculated using USP (2007) methods. The bulk volume
of the undisturbed powder when filled in a 50 mL graduated
cylinder was measured and bulk density [32] was calculated
using Venkel tapped density apparatus (Japan) after mechani-
cal 500 taps, which provided tapped density (TD). Hausner’s
ratio and compressibility index were calculated using equa-
tions 1 and 2 [33].
Hausner’s ratio TD BD= (1)









F1 ARM: APL300 1:1 10
F2 ARM: APL300 1:2 15
F3 ARM: APL300 1:3 20
F4 ARM: EXP. 9555 1:1 10
F5 ARM: EXP. 9555 1:2 15
F6 ARM: EXP. 9555 1:3 20
F7 ARM: EXP. 9560 1:1 10
F8 ARM: EXP. 9560 1:2 15
F9 ARM: EXP. 9560 1:3 20
F10 ARM: EXP. 9565 1:1 10
F11 ARM: EXP. 9565 1:2 15
F12 ARM: EXP. 9565 1:3 20
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Compressibility index TD BD TD= −( )100 (2)
2.2.8. Moisture content of ARM-PS carrier systems
Approximately 1–2 grams of ARM:PS system (F1–F12) were evalu-
ated for moisture content using the Citizen digital moisture
analyzer balance (India) and the moisture content was deter-
mined in percentage.
2.2.9. Encapsulation efficiency study
An amount of ARM:PS system (F1–F12) samples containing
about 40 mg of ARM was weighed and dissolved in sufficient
methanol to produce 100 mL. The resulting solution was fil-
tered using a sintered glass crucible, discarding the first 10 mL.
2 mL of the resulting solution was pipetted into a quick-fit test
tube and 2 mL of concentrated HCl was added. The test tube
was stoppered and allowed to stand in a water bath set to 30 °C
(or room temp.) for 25 minutes. The resulting solution was
diluted with sufficient methanol to 50 mL. The absorbance
reading at a wavelength maximum of 211 nm was taken against
a blank solution made up of 2 mL of HCl and 50 mL of metha-
nol.The encapsulation efficiency of ARM in the prepared ARM:PS
system was calculated from calibration curve.
2.2.10. Specific surface area and pore size distribution
The surface area of developed porous starch was determined
using nitrogen sorption isotherms through Brunauer–Emmett–
Teller (BET) protocol. Nitrogen sorption studies were done using
ASA P2020 (Micromeritics, USA). Before initiation of the study,
the powder sample was stored in sample bulb and then sub-
jected to 40 °C under vacuum of 0.1 mPa overnight to facilitate
removal of moisture from the sample. The nitrogen sorption
data were generated through a relative pressure (p/p0) range
of 0.0 to 1.0.
3. Results and discussion
3.1. Saturation solubility study
The saturation solubility study of the developed ARM:PS system
showed increase in drug solubility with increase in ratios of
respective porous silica. The solubility of neat ARM shows very
least solubility value of 0.0180 μg/mL in distilled water con-
taining 1% SLS. Fig. 2 shows the solubility data of ARM:PS
system of ARM with different porous silicas showed an im-
proved solubility profile compared to neat ARM in both
dissolution media. In F3 formulation batch of ARM with APL
300, EXP. 9555, EXP. 9560 and EXP. 9565 enhanced the solubil-
ity up to an extent F3 = 22.03 μg/mL, F6 = 32.04 μg/mL, F9 = 31.08
and F12 = 29.08 μg/mL respectively in dissolution medium of
distilled water containing 1% SLS.
The saturation solubility of ARM:PS systems was found
higher in medium 2 containing phosphate buffer (pH 7.2)
with 1% SLS with solubility values of ARM:PS systems
as F3 = 138.94 μg/mL, F6 = 137.84 μg/mL, F9 = 125.69 and
F12 = 119.65 μg/mL respectively. A linear relationship with
respect to increase in solubility of ARM to respective in-
creased ratios of porous silicas to drug was observed (Fig. 2).
The solubility data of ARM:PS systems with different porous
silicas showed an improved solubility profile compared to neat
ARM. As per the Noyes–Whitney equation [34,35], saturation
solubility and dissolution rate of a drug can be improved by
an increase in surface area of particles. In case of ARM:PS
system the drug is adsorbed in the pores of porous silica, re-
sulting in particle size reduction of drugs. The saturation
solubility results are in good agreement with Noyes–Whitney
equation [36]. The increase in solubility of system could be
due to improved wettability of ARM. Adsorption of drug
Fig. 2 – Solubility of ARM and SDs [Medium 1: Distilled water containing 1% SLS. Medium 2: Phosphate buffer pH 7.2
containing 1% SLS].
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particles in the pores of porous silica brought about a de-
crease in particle size of drugs which resulted in the formation
of amorphous ARM.
3.2. Differential scanning calorimetry studies
Thermal behavior of neat ARM, APL 300, EXP. 9555, EXP. 9560,
EXP. 9560, EXP. 9565, and ARM:PS systems F3, F6, F9, and F12 are
shown in Fig. 3.The pure ARM shows a sharp endothermic peak
at 86.64 °C, followed by exothermic peak at 172.21 °C with en-
thalpy change of 56.68 J/g, whereas APL 300 and other porous
silica did not show a melting endotherm because of its amor-
phous nature. The thermogram of ARM:PS systems showed a
slight decrease in ΔH and peak height, in accordance with XRD
diffractograms. In case of DSC analysis characteristic endother-
mic peak of ARM was shifted towards higher temperature with
reduced intensity in ARM:PS system.The F3, F6 and F12 showed
very small endothermic peak at a lower temperature compared
to neat ARM, indicating some crystallinity that may be due to
addition of excess amount of ARM in solvent evaporation process.
The heat of fusion of neat ARM was higher compared to that
of ARM:PS system. The heat of fusion decreased with increase
in carrier ratio. The DSC thermograms indicated that the crys-
talline nature of ARM was diminished in ARM:PS system with
increase in ratio of respective silicas. This could be attributed
to higher APL 300 and other porous silica concentration and
uniform distribution of ARM in the porous silica, resulting in
complete miscibility of drug in the carrier system.
3.3. X-ray diffraction studies
X-ray diffraction studies were performed to elucidate the physi-
cal state of the pure ARM in the ARM:PS system. The X-ray
diffractograms of ARM, APL 300, F1, F2 and F3, Exp. 9555, F4,
F5 and F6, Exp. 9560, F7, F8, and F9 and Exp. 9565, F10, F11, and
F12 are shown in Fig. 4a–d, respectively, which illustrates the
changes in drug crystallinity upon increasing ratios of respec-
tive porous silica. The X-ray diffractograms of ARM show
numerous distinct peaks at two-theta values of 7.29°, 10.04°,
18.04°, 19.68° and 22.1° indicating the crystalline nature of drug,
and the results are in agreement with previous literature [37,38].
All porous silicas are amorphous and do not produce any peaks.
The high intensity signal of ARM drug at two-theta value of
10.04° was found to be significantly reduced in the XRD of F3,
F2 and F1. Formulation systems F2 and F1 show intense peak
compared to F3 due to presence of ARM in greater amount.
X-ray diffraction studies were performed to study the physi-
cal nature of ARM loaded with respective silicas. In the case
of F5 and F6, the system does not show any intense peak in-
dicating complete amorphous state of formulation system.
Nevertheless F4 shows some intense peak indicating partial
amorphization. The formulation systems F7 to F9 and F10 to
F12 loaded with ARM shows high intensity signal of ARM at
two-theta value of 10.04° indicating partial adsorption of drug
into porous silica. A broadened peak of all ARM loaded silicas
at two-theta value of 22.10° could be contributed to the low-
ering of crystallite size of drug, thus indicating partial
amorphousness due to effect of drug loading on silica.
3.4. Scanning electron microscopy studies
SEM was used to determine the surface morphologies of pure
ARM, APL 300 and ARM:PS systems. As shown in Fig. 5, the SEM
micrographs of pure ARM revealed large crystalline particles
with cubic shape blocks, comparatively larger than ARM:PS
systems. The ARM:PS systems were found to be without sharp
edges. The solid dispersion particles had a reduced geometric
diameter at a range of several micrometers compared to pure
Fig. 3 – DSC thermograms of Artemether (a), APL 300 (b), Exp. 9555 (c), Exp. 9560 (d), Exp. 9565 (e), F3 (f), F6 (g), F9 (h), F12 (i).
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ARM as shown in Fig. 5 A–E. SEM study revelead that extensive
deposition of the ARM drug was observed on APL 300 as com-
pared to EXP. 9555, EXP. 9560 and EXP. 9565 porous silica. This
may be due to large surface area imparted by the porous nature
of silica.The ARM:PS systems appeared to be agglomerated with
smooth surface owing to presence of porous silica. The ARM:PS
systems showed more homogeneity with porous silica.
3.5. In vitro dissolution rate studies of ARM:PS systems
The in-vitro dissolution profiles of pure ARM and ARM:PS
systems prepared by solvent evaporation method are
represented in Fig. 6. The aqueous solubility of ARM is
0.019 μg/mL, which may be considered as practically in-
soluble. All solid dispersion systems displayed higher solubility
of ARM than pure drug. Enhancement in dissolution rate of
ARM:PS systems was observed in the following order: APL
300 > EXP. 9555 > EXP. 9560 > EXP. 9565 with percentage disso-
lution found (F3 = 68.9%), (F6 = 63.77%), (F9 = 60.04%), and
(F12 = 59.64%) respectively at end of T90 minutes compared with
neat ARM (28.16%).
The dissolution rate of ARM:PS systems has improved largely
than neat ARM, with increase in amount of respective porous
silica. The dissolution rate enhancement of ARM from drug-
Fig. 4 – (a) PXRD patterns of pure ARM and ARM loaded with APL300. (b) PXRD patterns of pure ARM and ARM loaded with
EXP. 9555. (c) PXRD patterns of pure ARM and ARM loaded with EXP. 9560. (d) PXRD patterns of pure ARM and ARM loaded
with EXP. 9565.
765a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 1 ( 2 0 1 6 ) 7 6 0 – 7 7 0
carrier systems was due to conversion of drug to amorphous
state and solubilization effect of porous silica as a carrier re-
sulting in enhanced wettability and an increased effective
surface area of ARM.The enhancement in solubility is the result
of disordered structure of amorphous solid that offers a lower
thermodynamic barrier to dissolution and formation disper-
sion where the drug is adsorbed inside pores of porous silicas.
An amorphous formulation system will dissolve at a faster rate
Fig. 5 – SEM images of pure ARM (Top left), and SD systems respectively F3 (A and B), F6 (C), F9 (D), F12 (E).
Fig. 6 – In vitro release of ARM SD formulation batches in phosphate buffer pH 7.2 containing 1% SLS (mean ± SD).
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because of its higher internal energy and superior molecular
motion [39]. The porous silica favors to insoluble ARM gets out
in open dissolution medium in the form of very fine particu-
late system for instant dissolution.
The results are in good agreement with that obtained from
DSC and XRD measurement that indicates drug incorporated
in porous structure of silica was in amorphous form. Disso-
lution efficiency (DE) is the area under the dissolution curve
between time points t1 and t2 expressed as a percentage of curve
at maximum dissolution, y100, over the same time period and












DE values indicate the real time dissolution rate of drug dis-
solved in dissolution medium. DE values of F3, F6, F9 and F12
were found to be 75.58, 72.34, 71.9 and 73.12 respectively. DE
values give us superior illustrative information with refer-
ence to in vivo performance.
3.6. Flow properties measurement
Powder flow and compaction behavior play an important role
in manufacturing, processing and packaging techniques. ARM:PS
systems were evaluated for powder flow properties and values
were found to be within the prescribed limits of all formula-
tions as shown in Table 2. All formulations exhibited good flow
property as expressed in terms of micrometric parameters as
per USP guidelines and found within limit.
3.7. Moisture content of ARM-PS carrier systems
Approximately 1.5–2 grams of ARM:PS systems were loaded on
pan on Citizen digital moisture analyzer balance (India) and
moisture content was determined in percentage. The mois-
ture content values are as shown in Table 3. The moisture
content values of all the developed formulation systems were
found within USP limits.
3.8. Content uniformity of ARM-PS carrier systems
The content uniformity of ARM in the ARM:PS systems were
found to be uniformly distributed. All the % content values were
found within range of 97–102% as per international pharma-
copoeia respective values of ARM:PS systems (Table 4). The
content of ARM was calculated from the calibration curve equa-
tion (y = 0.303x + 0.0148). Therefore, x obtained from standard
curve equation will correspond to: X*100/8 = X*12.5.The % assay
of ARM in the ARM:PS systems were found to be uniformly dis-
tributed. The content uniformity was found within range of
97–102% as per international pharmacopoeia.
3.9. Specific surface area and pore size distribution
The nitrogen adsorption and desorption behavior of all the
porous silica samples is shown in Fig. 7: APL 300 (A), Exp. 9555
(B), Exp. 9560 (C), Exp. 9565 (D). Specific surface area calcu-
lated from BET method was found to be 294.13 m2/g (A),
256.02 m2/g (B), 213.62 m2/g (C) and 207.22 m2/g respectively. All
the results showed type IV isotherm displaying a monolayer
adsorption followed by multilayer adsorption of nitrogen on
respective porous silicas. Nitrogen condensation step re-
sulted in two hysteresis loops. The curve also showed nitrogen
condensation step which is a distinct feature of porous ma-
terials [28]. The APL 300 showed highest specific surface area
as it is made by non-precipitation method; the other silicas
are made by precipitataion method. Because APL 300 has the
highest porous surface area, it showed the highest solubility
and dissolution rate compared to other porous silicas.
4. Conclusion
In the present study, dissolution rate enhancement potential of
porous silica for ARM is successfully demonstrated. The results
from FTIR chemical imaging, SEM, XRD and DSC analysis showed
that ARM in amorphous form could be incorporated into porous
silica by solvent evaporation method. The improved dissolu-
tion rate of ARM:PS systems is because of amorphous nature
Table 2 – Micrometrics properties of ARM:PS systems.
Parameters ARM: APL 300 ARM:EXP. 9555 ARM:EXP. 9560 ARM:EXP. 9565
Bulk density (gm/mL) 0.223 ± 0.003 0.222 ± 0.006 0.299 ± 0.003 0.222 ± 0.006
Tapped density (gm/mL) 0.279 ± 0.010 0.285 ± 0.013 0.341 ± 0.007 0.285 ± 0.011
Hausner’s ratio 1.24 ± 0.009 1.28 ± 0.015 1.31 ± 0.003 1.28 ± 0.012
Carr’s index 19.78 ± 0.014 22.1 ± 0.008 24.28 ± 0.03 22.1 ± 0.011
Angle of repose 24.35° ± 0.962 25.43° ± 1.01 29.35° ± 1.24 28.34° ± 1.13











1:1 6.612 9.015 5.435 6.667
1:2 6.602 9.019 5.445 6.670
1:3 6.622 9.033 5.450 6.660












1:1 100.88 101.57 100.74 101.29
1:2 97.71 99.91 98.95 97.99
1:3 99.91 97.30 97.99 98.54
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of ARM and better wetting properties induced by porous silica.
This technique can effectively be extrapolated to a number of
other poorly water-soluble drugs as a cost effective way of pre-
paring immediate release formulations.
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